Dr. Shirish Gadgeel discusses the activity of antibody drug conjugates against brain metastases in non-small cell lung cancer based on emerging data, suggesting superiority over chemotherapy.
Nivolumab/Chemoradiotherapy Regimen Misses PFS End Point in Unresectable, Locally Advanced NSCLC
Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection
FDA Grants Priority Review to Zenocutuzumab BLA for NRG1+ NSCLC and Pancreatic Cancer
Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers
Glecirasib Generates Durable Responses in Pretreated Advanced KRAS G12C+ NSCLC
Frontline Amivantamab Plus Chemo Receives Positive EU CHMP Opinion for EGFR Exon 20 Insertion+ NSCLC
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC